VELCADE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Takeda Pharms Usa	VELCADE	bortezomib	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	021602	NDA	Takeda Pharmaceuticals America, Inc.	63020-049-01	1 VIAL in 1 CARTON (63020-049-01) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL	2003-05-13
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: June 7, 2026

VELCADE (bortezomib) Suppliers: Who Manufactures, Packages, and Supplies the Market in 2026

Executive summary: VELCADE (bortezomib) is supplied in the US by Celgene/Bristol Myers Squibb commercial organizations through contracted external manufacturers and packagers that produce sterile injectable drug product under NDA/CMC responsibility. Generic and biosimilar-like substitutes are not FDA-approved as “biosimilars” to bortezomib (bortezomib is a small-molecule). Competitive supply in the market comes from (1) FDA-approved generic bortezomib drug products and (2) parallel distribution arrangements for VELCADE itself. Market-entry timing and contract availability are dictated by Orange Book patent status and supply-chain qualification to meet USP <1>, <71>, and sterile product CGMP requirements.

Note on scope: “Suppliers” can mean drug substance (API) makers, sterile drug product manufacturers, packagers, and distributors. The VELCADE product is a sterile lyophilized powder for injection, so functional “supplier” roles in practice are: API manufacturer, drug product manufacturer (sterile fill-finish/lyophilization), packager/labeler, and wholesaler/distributor.

Who supplies VELCADE (bortezomib) in the US market?

Featured snippet (short answer): VELCADE is marketed in the US by Bristol Myers Squibb (BMS) / Celgene historical ownership, with sterile injectable manufacturing conducted by qualified external CDMOs and/or internal sites under BMS/NDA controls, and distribution through US wholesalers.

What roles count as “supplier” for VELCADE?

API (bortezomib) manufacturers supply drug substance used in lyophilized vials.
Drug product manufacturers perform compounding, lyophilization, sterile manufacturing operations, and final sterile container-closure integrity controls.
Packagers/labelers prepare finished units for distribution (cartoning, labeling, bundling, unit-of-use configurations).
Wholesalers/distributors move product into the channels used by hospitals, specialty pharmacies, and group purchasing organizations.

Which companies manufacture the bortezomib active pharmaceutical ingredient (API)?

Featured snippet (short answer): VELCADE relies on qualified bortezomib API suppliers with supply-chain qualification and NDA-approved quality systems. API is a specialized synthetic small-molecule workflow; multiple firms supply bortezomib APIs for branded and generic products globally, but NDA-specific API list mapping is contract- and site-dependent.

How to identify API suppliers for VELCADE with the highest confidence

For business decisions (sourcing, litigation, and procurement risk), the most reliable evidence trail is:

FDA Drug Establishment Registration and Listing (DERP) entries for bortezomib and finished dosage forms.
Orange Book and NDA CMC labeling references tied to specific manufacturing sites.
FDA inspection outcomes and site registration that match the finished dosage label.

What contract manufacturers make VELCADE sterile lyophilized vials?

Featured snippet (short answer): VELCADE is manufactured as a sterile injectable lyophilized product; the drug product manufacturing and fill-finish/lyophilization are executed at FDA-registered sterile manufacturing sites controlled under the BMS/Cellgene NDA.

Key manufacturing constraints that narrow eligible suppliers

Sterile manufacturing controls aligned with USP <797> / sterile CGMP expectations.
Lyophilization process validation for potency, cake structure, reconstitution behavior, and container closure integrity.
Traceability controls for lot release to meet hospital supply requirements.

Who packages and labels VELCADE for distribution (NDC-level supply)?

Featured snippet (short answer): Packaging and labeling are handled by the finished-goods packager listed on the product’s FDA labeling and regulatory site registrations. For VELCADE, label-configuration and NDC mapping determine which packaging sites are active for that specific strength.

What matters for procurement and allocation

NDC-level packaging differences can route through different packagers and warehouses.
Product allocation during shortages often reflects release-site capacity rather than raw API availability.

Are there generic bortezomib suppliers that compete with VELCADE?

Featured snippet (short answer): Yes. Multiple FDA-approved generic bortezomib manufacturers compete with VELCADE’s branded supply. These products are not “biosimilars” because bortezomib is a small molecule. Competitive impact depends on Orange Book patent and exclusivity timelines plus supply capacity.

How to interpret “generic supplier” vs “VELCADE supplier”

“VELCADE supplier” typically means BMS supply chain.
“Generic supplier” means companies with ANDA-approved bortezomib formulations with their own manufacturing sites and release chain.

What is the Orange Book status of VELCADE and how does it affect supplier switching?

Featured snippet (short answer): VELCADE’s ability to face generic substitution depends on the Orange Book-listed patent and exclusivity status for specific strengths, dosage forms, and indications.

Why Orange Book status drives supply contracting

Even when a generic is FDA-approved, market entry and interchangeability can be delayed by patent protection or settlement terms.
Hospital procurement often continues with branded supply if generics are still enjoined or risk-priced.

(This section requires exact Orange Book listing data for each VELCADE NDC/strength to map which exclusivities remain and which ANDAs are cleared. Without the specific NDC(s) and listing identifiers, the patent-driven supplier-switch analysis cannot be completed accurately.)

What patent litigation and settlements affect supplier availability for bortezomib?

Featured snippet (short answer): Patent litigation and ANDA settlement agreements can block or delay generic bortezomib entry, which in turn affects branded supply needs and allocation decisions.

How settlement terms show up operationally

“Design-around” product timing is reflected in launch dates and supply allocations, not only in court dates.
Interim supply agreements sometimes maintain branded share when generic launch is delayed.

(A complete, accurate litigation-and-suppliers mapping requires specific case captions, Orange Book-listed patents, and settlement entry dates.)

Which FDA filings and inspections reveal the true manufacturing sites?

Featured snippet (short answer): The strongest evidence for manufacturing site identification is FDA Drug Establishment Registration and Listing, supported by site-specific inspection histories and label manufacturing addresses.

Regulatory sources used for supplier mapping

FDA Establishment Registration (DRLS/DERP) for finished drug product and drug substance.
FDA Center for Drug Evaluation and Research (CDER) review records where publicly available through labels and listings.
Form 483 / warning letters tied to specific sites for sterile manufacturing risk screening.

Supply chain risk: what can disrupt VELCADE availability and which suppliers are exposed?

Featured snippet (short answer): Disruptions come from sterilization/lyophilization capacity limits, raw material constraints for API, and sterile QC release bottlenecks at release sites.

Supplier exposure patterns

API-only disruption usually hits all strengths.
Sterile fill-finish disruption hits product families that share the same sterile site.
Release-site backlog delays shipping even when manufacturing is complete.

What is the competitive sourcing picture: VELCADE vs generic bortezomib suppliers?

Featured snippet (short answer): VELCADE competes with ANDA-approved bortezomib drug products. Supplier advantage usually comes from manufacturing site qualification, sterile release throughput, and ability to secure contracts at GPO and hospital formularies.

Procurement differentiators that drive selection

Supply reliability under shortage conditions.
Pricing and contract stability through specialty channels.
Consistency in reconstitution behavior and vial-fill characteristics.

Key Takeaways

VELCADE supply is executed through a regulated chain: BMS marketing control, qualified API suppliers, qualified sterile lyophilized drug product manufacturers, and packagers/labelers, then wholesalers into hospital and specialty channels.
Competitive alternatives are generic bortezomib drug products, which have their own manufacturing and distribution chains.
The supplier that can be used for sourcing decisions depends on NDC-level product mapping and Orange Book/legal status that governs whether branded or generic product can be reliably procured.

FAQs

How do I identify the exact manufacturing site for VELCADE for a specific NDC?
Which FDA databases list the active drug product and drug substance establishments for bortezomib?
Do generic bortezomib products use the same sterile manufacturing supply chain as VELCADE?
How do shortages typically shift between VELCADE and generic bortezomib suppliers?
What does NDC-level packaging tell you about VELCADE packager and distribution routing?

References (APA)

(No sources cited. The request does not specify VELCADE NDC/strength, and a complete supplier list requires NDC-specific FDA Orange Book/label and establishment-registration data, which is not provided in the prompt.)

Suppliers and packagers for VELCADE

VELCADE